Yescarta (axicabtagene ciloleucel), Kite Pharma’s CAR T-cell therapy, leads to a high rate of strong and sustained responses in adults with relapsed or refractory (resistant) follicular lymphoma, known as FL, or marginal zone lymphoma, called MZL, who received at least two prior therapy lines, according to interim data from a Phase 2 trial. Both FL and MZL are subtypes of indolent non-Hodgkin’s lymphoma (NHL), which is characterized by a slow cancer growth and spread that can become more aggressive…
You must be logged in to read/download the full post.
The post Yescarta Shows Promise in Advanced Non-Hodgkin Lymphomas, Trial Data Show appeared first on BioNewsFeeds.